William Blair Comments on Kezar Life Sciences, Inc.’s Q3 2024 Earnings (NASDAQ:KZR)

Kezar Life Sciences, Inc. (NASDAQ:KZR) – Stock analysts at William Blair upped their Q3 2024 earnings per share (EPS) estimates for shares of Kezar Life Sciences in a report released on Tuesday, August 13th. William Blair analyst M. Phipps now anticipates that the company will post earnings of ($0.30) per share for the quarter, up from their previous estimate of ($0.34). The consensus estimate for Kezar Life Sciences’ current full-year earnings is ($1.24) per share. William Blair also issued estimates for Kezar Life Sciences’ Q4 2024 earnings at ($0.37) EPS, FY2024 earnings at ($1.25) EPS, Q1 2025 earnings at ($0.35) EPS, Q2 2025 earnings at ($0.35) EPS, Q3 2025 earnings at ($0.36) EPS, Q4 2025 earnings at ($0.36) EPS, FY2025 earnings at ($1.42) EPS, FY2026 earnings at ($1.53) EPS and FY2027 earnings at ($1.65) EPS.

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $7.00 price objective on shares of Kezar Life Sciences in a research note on Wednesday.

Kezar Life Sciences Stock Performance

Shares of Kezar Life Sciences stock opened at $0.61 on Friday. The company has a quick ratio of 11.49, a current ratio of 11.48 and a debt-to-equity ratio of 0.05. The stock’s fifty day moving average is $0.63 and its two-hundred day moving average is $0.77. Kezar Life Sciences has a 52 week low of $0.54 and a 52 week high of $1.69. The company has a market capitalization of $44.66 million, a PE ratio of -0.44 and a beta of 0.28.

Institutional Trading of Kezar Life Sciences

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Vanguard Group Inc. lifted its position in Kezar Life Sciences by 1.0% during the 1st quarter. Vanguard Group Inc. now owns 3,094,224 shares of the company’s stock worth $2,790,000 after acquiring an additional 30,740 shares during the period. Acadian Asset Management LLC raised its stake in shares of Kezar Life Sciences by 3.6% during the 2nd quarter. Acadian Asset Management LLC now owns 1,855,194 shares of the company’s stock valued at $1,112,000 after buying an additional 64,356 shares during the last quarter. Affinity Asset Advisors LLC purchased a new position in shares of Kezar Life Sciences during the 1st quarter valued at about $1,588,000. Acuitas Investments LLC raised its stake in shares of Kezar Life Sciences by 42.8% during the 2nd quarter. Acuitas Investments LLC now owns 986,785 shares of the company’s stock valued at $592,000 after buying an additional 295,956 shares during the last quarter. Finally, Ikarian Capital LLC raised its stake in shares of Kezar Life Sciences by 1.8% during the 1st quarter. Ikarian Capital LLC now owns 868,992 shares of the company’s stock valued at $783,000 after buying an additional 15,601 shares during the last quarter. Institutional investors and hedge funds own 67.90% of the company’s stock.

Kezar Life Sciences Company Profile

Kezar Life Sciences, Inc, a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis.